

REMARKS

In response to the Official Action dated August 5, 2009 in which restriction has been required, Applicants hereby elect the invention identified as Group VI, i.e. claim 17 directed to a method for treating Alzheimer's disease, comprising administering the adeno-associated virus vector of claim 1 in a therapeutically effective amount to a subject.

All of previous claims 1-18 have been cancelled and have been replaced by new claims 19-29 directed to the elected invention.

In the new claims, new claim 19 is presented in independent form, combining claims 1 and 17.

The remaining claims depend on claim 19 and contain features from previous claims 3, 4, 6, 7, 9, 10, 12-14 and 16.

Favorable action on the merits is now requested.

Respectfully submitted,

Takeshi TABIRA et al.

By _____

Matthew M. Jacob

Registration No. 25,154

Attorney for Applicants

MJ/kjf

Washington, D.C. 20005-1503

Telephone (202) 721-8200

Facsimile (202) 721-8250

September 1, 2009